Absorption and metabolism of nafarelin, a potent agonist of gonadotropin-releasing hormone. 1988

R L Chan, and M R Henzl, and M E LePage, and J LaFargue, and C A Nerenberg, and S Anik, and M D Chaplin
Department of Reproductive Medicine, Syntex Research, Palo Alto, CA 94304.

Nafarelin, a potent gonadotropin-releasing hormone (GnRH) agonist, was absorbed rapidly into systemic circulation (time to reach peak concentration, 20 to 40 minutes) after intranasal but not after sublingual or vaginal administration. Serum elimination half-life was about 2 hours. Nasal absorption of nafarelin was increased by increasing the concentration of the drug in the dose solution and incorporating sodium glycocholate into the nasal formulation. An optimal formulation providing maximum nasal absorption of nafarelin was one containing 1.75 mg nafarelin per ml and 2% sodium glycocholate. Bioavailability of this nasal formulation relative to a single subcutaneous dose averaged 21%. The metabolism and excretion of nafarelin were determined in three subjects after subcutaneous administration of [14C]-nafarelin. Radioactivity was excreted in approximately equal amounts in urine and stool. Six metabolites accounted for most of the radioactivity in urine. Four metabolites were short peptide fragments of nafarelin and the other metabolites were naphthylalanine and 2-naphthylacetic acid.

UI MeSH Term Description Entries
D007279 Injections, Subcutaneous Forceful administration under the skin of liquid medication, nutrient, or other fluid through a hollow needle piercing the skin. Subcutaneous Injections,Injection, Subcutaneous,Subcutaneous Injection
D007987 Gonadotropin-Releasing Hormone A decapeptide that stimulates the synthesis and secretion of both pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE. GnRH is produced by neurons in the septum PREOPTIC AREA of the HYPOTHALAMUS and released into the pituitary portal blood, leading to stimulation of GONADOTROPHS in the ANTERIOR PITUITARY GLAND. FSH-Releasing Hormone,GnRH,Gonadoliberin,Gonadorelin,LH-FSH Releasing Hormone,LHRH,Luliberin,Luteinizing Hormone-Releasing Hormone,Cystorelin,Dirigestran,Factrel,Gn-RH,Gonadorelin Acetate,Gonadorelin Hydrochloride,Kryptocur,LFRH,LH-RH,LH-Releasing Hormone,LHFSH Releasing Hormone,LHFSHRH,FSH Releasing Hormone,Gonadotropin Releasing Hormone,LH FSH Releasing Hormone,LH Releasing Hormone,Luteinizing Hormone Releasing Hormone,Releasing Hormone, LHFSH
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006000 Glycocholic Acid The glycine conjugate of CHOLIC ACID. It acts as a detergent to solubilize fats for absorption and is itself absorbed. Cholylglycine,Glycine Cholate,Glycocholate,Glycocholate Sodium,Glycocholic Acid, Sodium Salt
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R L Chan, and M R Henzl, and M E LePage, and J LaFargue, and C A Nerenberg, and S Anik, and M D Chaplin
November 1985, Fertility and sterility,
R L Chan, and M R Henzl, and M E LePage, and J LaFargue, and C A Nerenberg, and S Anik, and M D Chaplin
October 1988, The Journal of clinical endocrinology and metabolism,
R L Chan, and M R Henzl, and M E LePage, and J LaFargue, and C A Nerenberg, and S Anik, and M D Chaplin
October 1986, The Journal of clinical endocrinology and metabolism,
R L Chan, and M R Henzl, and M E LePage, and J LaFargue, and C A Nerenberg, and S Anik, and M D Chaplin
December 1990, DICP : the annals of pharmacotherapy,
R L Chan, and M R Henzl, and M E LePage, and J LaFargue, and C A Nerenberg, and S Anik, and M D Chaplin
January 1985, Drug metabolism and disposition: the biological fate of chemicals,
R L Chan, and M R Henzl, and M E LePage, and J LaFargue, and C A Nerenberg, and S Anik, and M D Chaplin
June 1985, Fertility and sterility,
R L Chan, and M R Henzl, and M E LePage, and J LaFargue, and C A Nerenberg, and S Anik, and M D Chaplin
January 1985, Drug metabolism and disposition: the biological fate of chemicals,
R L Chan, and M R Henzl, and M E LePage, and J LaFargue, and C A Nerenberg, and S Anik, and M D Chaplin
November 1990, American journal of obstetrics and gynecology,
R L Chan, and M R Henzl, and M E LePage, and J LaFargue, and C A Nerenberg, and S Anik, and M D Chaplin
January 1982, International journal of fertility,
R L Chan, and M R Henzl, and M E LePage, and J LaFargue, and C A Nerenberg, and S Anik, and M D Chaplin
December 1986, The Journal of clinical endocrinology and metabolism,
Copied contents to your clipboard!